159 related articles for article (PubMed ID: 32233239)
1. [Methods for androgen receptor splice variant-7 detection: Advances in studies].
Li K; Fan GR; Chen CH; Wang ZP
Zhonghua Nan Ke Xue; 2019 Nov; 25(11):1031-1035. PubMed ID: 32233239
[TBL] [Abstract][Full Text] [Related]
2. [ARV-7: A biomarker for the treatment of metastatic castration-resistant prostate cancer].
Chen ZY; Dong Q; Liu LR; Wei Q
Zhonghua Nan Ke Xue; 2019 Feb; 25(2):172-176. PubMed ID: 32216207
[TBL] [Abstract][Full Text] [Related]
3. [Splice variant AR-V7 : Is it time for its routine use as a predictive marker in prostate cancer?].
Tsaur I; Becker C; Thelen P; Roos FC
Urologe A; 2017 Sep; 56(9):1164-1167. PubMed ID: 28702748
[TBL] [Abstract][Full Text] [Related]
4. Standardization of CTC AR-V7 PCR assay and evaluation of its role in castration resistant prostate cancer progression.
Tommasi S; Pilato B; Carella C; Lasorella A; Danza K; Vallini I; De Summa S; Naglieri E
Prostate; 2019 Jan; 79(1):54-61. PubMed ID: 30141201
[TBL] [Abstract][Full Text] [Related]
5. AR-V7 Transcripts in Whole Blood RNA of Patients with Metastatic Castration Resistant Prostate Cancer Correlate with Response to Abiraterone Acetate.
Todenhöfer T; Azad A; Stewart C; Gao J; Eigl BJ; Gleave ME; Joshua AM; Black PC; Chi KN
J Urol; 2017 Jan; 197(1):135-142. PubMed ID: 27436429
[TBL] [Abstract][Full Text] [Related]
6. Novel Junction-specific and Quantifiable In Situ Detection of AR-V7 and its Clinical Correlates in Metastatic Castration-resistant Prostate Cancer.
Zhu Y; Sharp A; Anderson CM; Silberstein JL; Taylor M; Lu C; Zhao P; De Marzo AM; Antonarakis ES; Wang M; Wu X; Luo Y; Su N; Nava Rodrigues D; Figueiredo I; Welti J; Park E; Ma XJ; Coleman I; Morrissey C; Plymate SR; Nelson PS; de Bono JS; Luo J
Eur Urol; 2018 May; 73(5):727-735. PubMed ID: 28866255
[TBL] [Abstract][Full Text] [Related]
7. Serial blood-based analysis of AR-V7 in men with advanced prostate cancer.
Nakazawa M; Lu C; Chen Y; Paller CJ; Carducci MA; Eisenberger MA; Luo J; Antonarakis ES
Ann Oncol; 2015 Sep; 26(9):1859-1865. PubMed ID: 26117829
[TBL] [Abstract][Full Text] [Related]
8. [AR-V7 Androgen Receptor Variant as a Predictor of Response to Androgen-receptor Targeting Agents Used to Treat Castration-refractory Metastatic Prostate Cancer].
Büchler T; Bobek V; Kološtová K
Klin Onkol; 2017; 31(1):9-14. PubMed ID: 29488772
[TBL] [Abstract][Full Text] [Related]
9. Androgen Receptor Splice Variant, AR-V7, as a Biomarker of Resistance to Androgen Axis-Targeted Therapies in Advanced Prostate Cancer.
Zhang T; Karsh LI; Nissenblatt MJ; Canfield SE
Clin Genitourin Cancer; 2020 Feb; 18(1):1-10. PubMed ID: 31653572
[TBL] [Abstract][Full Text] [Related]
10. Branched Chain RNA In Situ Hybridization for Androgen Receptor Splice Variant AR-V7 as a Prognostic Biomarker for Metastatic Castration-Sensitive Prostate Cancer.
Saylor PJ; Lee RJ; Arora KS; Deshpande V; Hu R; Olivier K; Meneely E; Rivera MN; Ting DT; Wu CL; Miyamoto DT
Clin Cancer Res; 2017 Jan; 23(2):363-369. PubMed ID: 27440270
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Value of Androgen Receptor Splice Variant 7 in the Treatment of Castration-resistant Prostate Cancer with Next generation Androgen Receptor Signal Inhibition: A Systematic Review and Meta-analysis.
Li H; Wang Z; Tang K; Zhou H; Liu H; Yan L; Guan W; Chen K; Xu H; Ye Z
Eur Urol Focus; 2018 Jul; 4(4):529-539. PubMed ID: 28753843
[TBL] [Abstract][Full Text] [Related]
12. Development of AR-V7 as a putative treatment selection marker for metastatic castration-resistant prostate cancer.
Luo J
Asian J Androl; 2016; 18(4):580-5. PubMed ID: 27174161
[TBL] [Abstract][Full Text] [Related]
13. AR-V7 as a Biomarker for Resistance to Treatment with Abiraterone/Enzalutamide in Three Latin American Countries: A Hypothetical Cost-Saving Analysis.
Pacheco-Orozco RA; Montealegre-Páez L; Cayol F; Martínez-Gregorio H; Oliver J; Frecha C; Vaca-Paniagua F; Perdomo S
Oncologist; 2020 Dec; 25(12):e1990-e1995. PubMed ID: 32721059
[TBL] [Abstract][Full Text] [Related]
14. The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients.
Del Re M; Biasco E; Crucitta S; Derosa L; Rofi E; Orlandini C; Miccoli M; Galli L; Falcone A; Jenster GW; van Schaik RH; Danesi R
Eur Urol; 2017 Apr; 71(4):680-687. PubMed ID: 27733296
[TBL] [Abstract][Full Text] [Related]
15. Antibody selection influences the detection of AR-V7 in primary prostate cancer.
Kaczorowski A; Chen X; Herpel E; Merseburger AS; Kristiansen G; Bernemann C; Hohenfellner M; Cronauer MV; Duensing S
Cancer Treat Res Commun; 2020; 24():100186. PubMed ID: 32619831
[TBL] [Abstract][Full Text] [Related]
16. Clinical Relevance of Androgen Receptor Splice Variants in Castration-Resistant Prostate Cancer.
Maughan BL; Antonarakis ES
Curr Treat Options Oncol; 2015 Dec; 16(12):57. PubMed ID: 26537882
[TBL] [Abstract][Full Text] [Related]
17. Analytical Validation of Androgen Receptor Splice Variant 7 Detection in a Clinical Laboratory Improvement Amendments (CLIA) Laboratory Setting.
Lokhandwala PM; Riel SL; Haley L; Lu C; Chen Y; Silberstein J; Zhu Y; Zheng G; Lin MT; Gocke CD; Partin AW; Antonarakis ES; Luo J; Eshleman JR
J Mol Diagn; 2017 Jan; 19(1):115-125. PubMed ID: 27916435
[TBL] [Abstract][Full Text] [Related]
18. Growth Inhibition by Testosterone in an Androgen Receptor Splice Variant-Driven Prostate Cancer Model.
Nakata D; Nakayama K; Masaki T; Tanaka A; Kusaka M; Watanabe T
Prostate; 2016 Dec; 76(16):1536-1545. PubMed ID: 27473672
[TBL] [Abstract][Full Text] [Related]
19. Assessment of Androgen Receptor Splice Variant-7 as a Biomarker of Clinical Response in Castration-Sensitive Prostate Cancer.
Sowalsky AG; Figueiredo I; Lis RT; Coleman I; Gurel B; Bogdan D; Yuan W; Russo JW; Bright JR; Whitlock NC; Trostel SY; Ku AT; Patel RA; True LD; Welti J; Jimenez-Vacas JM; Rodrigues DN; Riisnaes R; Neeb A; Sprenger CT; Swain A; Wilkinson S; Karzai F; Dahut WL; Balk SP; Corey E; Nelson PS; Haffner MC; Plymate SR; de Bono JS; Sharp A
Clin Cancer Res; 2022 Aug; 28(16):3509-3525. PubMed ID: 35695870
[TBL] [Abstract][Full Text] [Related]
20. Androgen Receptor Variant AR-V9 Is Coexpressed with AR-V7 in Prostate Cancer Metastases and Predicts Abiraterone Resistance.
Kohli M; Ho Y; Hillman DW; Van Etten JL; Henzler C; Yang R; Sperger JM; Li Y; Tseng E; Hon T; Clark T; Tan W; Carlson RE; Wang L; Sicotte H; Thai H; Jimenez R; Huang H; Vedell PT; Eckloff BW; Quevedo JF; Pitot HC; Costello BA; Jen J; Wieben ED; Silverstein KAT; Lang JM; Wang L; Dehm SM
Clin Cancer Res; 2017 Aug; 23(16):4704-4715. PubMed ID: 28473535
[No Abstract] [Full Text] [Related]
[Next] [New Search]
